Value
4.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 4.0 |
NUVL · Why this verdict
Why Nuvalent (NUVL) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Nuvalent is a clinical-stage biotech with strong price momentum supported by a golden cross and rising on-balance volume, but it has missed EPS estimates in all 4 of the last quarters and carries a weak Piotroski score of 2/9, making quality the dominant risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The bear case explicitly flags pipeline concentration in zidesamtinib, neladalkib, and NVL-330 as a concentration risk, meaning the company's entire valuation rests on a small number of clinical outcomes with no approved revenue. Bear case | At least 1 pipeline asset reports positive clinical data within 12 months without a material setback to the other programs. | →Stable |
| CounterPipeline concentration is common at this stage; the diversification across 3 programs actually provides more shots on goal than a single-asset biotech, potentially reducing binary risk. | ||
A golden cross pattern, RSI of 63, bullish MACD, and rising on-balance volume all confirm that price momentum is positive, which historically precedes further near-term price appreciation in breakout setups. Momentum breakdown | Price remains above the 200-day moving average for at least 6 consecutive months, confirming momentum sustains rather than reverting. | →Stable |
| CounterMomentum can evaporate quickly for pre-revenue biotechs if a clinical trial read-out disappoints, and the current price is already above analyst resistance at $121.15. | ||
A Piotroski F-Score of 2/9 is among the weakest possible readings, indicating broad failure across profitability, leverage, and efficiency metrics that makes the quality floor a material investment risk. Quality breakdown | Piotroski F-Score improves to 4 or higher within 4 reporting quarters as revenue begins to contribute to profitability metrics. | →Stable |
| CounterPre-revenue biotechs structurally fail most Piotroski tests; the score is not meaningful until the company has commercial operations, so it may overstate near-term risk. | ||
Nuvalent has missed EPS estimates in all 4 of the last reported quarters, with an average negative surprise of 16.6%, suggesting expenses are consistently exceeding what analysts model. Earnings | EPS surprise falls below negative 5% in fewer than 3 of the next 4 quarters, indicating the miss rate is improving. | →Stable |
| CounterIn clinical-stage companies, EPS misses often reflect higher-than-expected R&D investment into promising programs rather than operational failure, which can be a positive signal for pipeline advancement. | ||
The bear case explicitly flags pipeline concentration in zidesamtinib, neladalkib, and NVL-330 as a concentration risk, meaning the company's entire valuation rests on a small number of clinical outcomes with no approved revenue.
→StableBear case
- Expectation
- At least 1 pipeline asset reports positive clinical data within 12 months without a material setback to the other programs.
CounterPipeline concentration is common at this stage; the diversification across 3 programs actually provides more shots on goal than a single-asset biotech, potentially reducing binary risk.
A golden cross pattern, RSI of 63, bullish MACD, and rising on-balance volume all confirm that price momentum is positive, which historically precedes further near-term price appreciation in breakout setups.
→StableMomentum breakdown
- Expectation
- Price remains above the 200-day moving average for at least 6 consecutive months, confirming momentum sustains rather than reverting.
CounterMomentum can evaporate quickly for pre-revenue biotechs if a clinical trial read-out disappoints, and the current price is already above analyst resistance at $121.15.
A Piotroski F-Score of 2/9 is among the weakest possible readings, indicating broad failure across profitability, leverage, and efficiency metrics that makes the quality floor a material investment risk.
→StableQuality breakdown
- Expectation
- Piotroski F-Score improves to 4 or higher within 4 reporting quarters as revenue begins to contribute to profitability metrics.
CounterPre-revenue biotechs structurally fail most Piotroski tests; the score is not meaningful until the company has commercial operations, so it may overstate near-term risk.
Nuvalent has missed EPS estimates in all 4 of the last reported quarters, with an average negative surprise of 16.6%, suggesting expenses are consistently exceeding what analysts model.
→StableEarnings
- Expectation
- EPS surprise falls below negative 5% in fewer than 3 of the next 4 quarters, indicating the miss rate is improving.
CounterIn clinical-stage companies, EPS misses often reflect higher-than-expected R&D investment into promising programs rather than operational failure, which can be a positive signal for pipeline advancement.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.8 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.6 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 87)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.8 |
| Analyst rating | 5.0 |
| Price target | 5.5 |
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $18,421,691 (0.189% of mkt cap)
Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 3.3 |
| growth rank | 5.0 |
Technical
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.0 |
| support resistance | 0.0 |
| 52w position | 10.0 |
Risk (lower is worse)
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.4 |
| days to cover | 0.4 |
| volatility | 5.2 |
| put call | 10.0 |
| implied vol | 8.2 |
| beta | 6.4 |
| news risk | 5.0 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 8.0 |
- ▸Earnings concerns: 0B/4M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:6.5>=5.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:43d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.5=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.45
Upside
-6.7%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Momentum at 6.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.5=NEGATIVE.
The strongest dimensions are Momentum at 6.5, Risk (lower is worse) at 5.7, and Sentiment at 5.4; the weakest are Quality at 1.2, Insider at 3.3, and Catalyst at 3.6. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.45 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1A golden cross pattern, RSI of 63, bullish MACD, and rising on-balance volume all confirm that price momentum is positive, which historically precedes further near-term price appreciation in breakout setups.
Trip ifPrice falls below the 200-day moving average and stays below for more than 20 trading days.
- P2The bear case explicitly flags pipeline concentration in zidesamtinib, neladalkib, and NVL-330 as a concentration risk, meaning the company's entire valuation rests on a small number of clinical outcomes with no approved revenue.
Trip ifAny 1 of the 3 named pipeline programs receives a clinical hold or reports negative phase data, reducing the pipeline to fewer than 2 active programs.
- P3A Piotroski F-Score of 2/9 is among the weakest possible readings, indicating broad failure across profitability, leverage, and efficiency metrics that makes the quality floor a material investment risk.
Trip ifPiotroski F-Score remains below 3 for more than 4 consecutive quarters.
- P4Nuvalent has missed EPS estimates in all 4 of the last reported quarters, with an average negative surprise of 16.6%, suggesting expenses are consistently exceeding what analysts model.
Trip ifEPS surprise falls below negative 20% in at least 3 of the next 4 quarters.